Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/177014
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment |
Autor: | Leurs, Cyra E.; Podlesniy, Petar CSIC ORCID; Trullas, Ramón CSIC ORCID; Balk, Lisanne; Steenwijk, Martijn D.; Malekzadeh, Arjan; Fredrik Piehl,; Uitdehaag, Bernard M. J.; Killestein, Joep; Horssen, Jack van; Teunissen, C. E. | Palabras clave: | Multiple sclerosis Biomarkers Mitochondrial DNA Cerebrospinal fluid Digital PCR |
Fecha de publicación: | 1-abr-2018 | Editor: | Sage Publications | Citación: | Multiple Sclerosis 24(4): 472-480 (2018) | Resumen: | [Background] Mitochondrial dysfunction is increasingly recognized as an important feature of multiple sclerosis (MS) pathology and may be relevant for clinical disease progression. However, it is unknown whether mitochondrial DNA (mtDNA) levels in the cerebrospinal fluid (CSF) associate with disease progression and therapeutic response. [Objectives] To evaluate whether CSF concentrations of mtDNA in MS patients can serve as a marker of ongoing neuropathology and may be helpful to differentiate between MS disease subtypes. To explore the effect of disease-modifying therapies on mtDNA levels in the CSF. [Methods] CSF mtDNA was measured using a digital polymerase chain reaction (PCR) CSF mtDNA in two independent MS cohorts. The cohorts included 92 relapsing-remitting multiple sclerosis (RRMS) patients, 40 progressive multiple sclerosis (PMS) patients (27 secondary progressive and 13 primary progressive), 50 various neurologic disease controls, and 5 healthy controls. [Results] Patients with PMS showed a significant increase in CSF mtDNA compared to non-inflammatory neurologic disease controls. Patients with higher T2 lesion volumes and lower normalized brain volumes showed increased concentration of mtDNA. Patients treated with fingolimod had significantly lower mtDNA copy levels at follow-up compared to baseline. [Conclusion] Our results showed a non-specific elevation of concentration of mtDNA in PMS patients. mtDNA concentrations respond to fingolimod and may be used to monitor biological effect of this treatment | Versión del editor: | https://doi.org/10.1177/1352458517699874 | URI: | http://hdl.handle.net/10261/177014 | DOI: | 10.1177/1352458517699874 | ISSN: | 1352-4585 | E-ISSN: | 1477-0970 |
Aparece en las colecciones: | (IIBB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Cerebrospinal_Leurs.pdf | 126,69 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
18
checked on 22-abr-2024
SCOPUSTM
Citations
33
checked on 23-abr-2024
WEB OF SCIENCETM
Citations
25
checked on 28-feb-2024
Page view(s)
192
checked on 23-abr-2024
Download(s)
177
checked on 23-abr-2024